Legal & General Group
BLCM

Legal & General Group’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Legal & General Group’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-593
Closed -$12K – 3441
2019
Q2 		$12K Hold
593
– – ﹤0.01% 3332
2019
Q1 		$20K Hold
593
– – ﹤0.01% 3101
2018
Q4 		$17K Hold
593
– – ﹤0.01% 3155
2018
Q3 		$37K Hold
593
– – ﹤0.01% 2930
2018
Q2 		$44K Buy
593
+69
+13% +$5.38K ﹤0.01% 2807
2018
Q1 		$34K Sell
524
-171
-25% -$12.9K ﹤0.01% 2931
2017
Q4 		$58K Hold
695
– – ﹤0.01% 2826
2017
Q3 		$80K Buy
695
+122
+21% +$12.8K ﹤0.01% 2752
2017
Q2 		$67K Buy
573
+98
+21% +$12.2K ﹤0.01% 2819
2017
Q1 		$58K Sell
475
-18
-4% -$2.36K ﹤0.01% 2824
2016
Q4 		$68K Buy
493
+207
+72% +$36.7K ﹤0.01% 2776
2016
Q3 		$56K Hold
286
– – ﹤0.01% 2466
2016
Q2 		$36K Buy
+286
New +$31.8K ﹤0.01% 2643

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Legal & General Group's BLCM Position: Q3 2019 in Review

Legal & General Group sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2019, closing a stake of 593 shares — an estimated $12K sold.

Legal & General Group first reported a position in BLCM in Q2 2016 and held it in 13 quarters. The position peaked at $80K in Q3 2017. 67 funds tracked by Wall St. Rank hold BLCM as of Q3 2019.

  • Legal & General Group reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Legal & General Group sold 593 Bellicum Pharmaceuticals, Inc. shares in Q3 2019, an estimated $12K.
  • Legal & General Group first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2016 and held it in 13 quarters.
  • Legal & General Group's Bellicum Pharmaceuticals, Inc. position peaked at $80K in Q3 2017.
  • 67 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2019.

Based on Legal & General Group's 13F filing for Q3 2019, filed 13 Nov 2019.